Showing results (391-400 of 424) with videos related to

Sort By:
Pageof 43
Clinical Lung Cancer|March 20, 2016
Prognostic Impact of Multiple Clinicopathologic Risk Factors and c-MET Overexpression in Patients Who Have Undergone Resection of Stage IB Non-Small-Cell Lung CancerIn-Ho Kim, In Hee Lee, Ji Eun Lee, et al.
Nature Communications|February 10, 2022
Development and validation of a prognostic and predictive 32-gene signature for gastric cancerJae-Ho Cheong, Sam C Wang, Sunho Park, et al.
Annals of Surgical Oncology|October 4, 2016
Clinical Significance of C-MET Overexpression and Epidermal Growth Factor Receptor Mutation in Platinum-Based Adjuvant Chemotherapy Outcome in Surgically Resected Lung AdenocarcinomaIn-Ho Kim, In Hee Lee, Ji Eun Lee, et al.
Thrombosis Research|August 21, 2012
Seasonal variation in the occurrence of venous thromboembolism: a report from the Korean Venous Thromboembolism Working PartyMoon Ju Jang, Hee-Jin Kim, Soo-Mee Bang, et al.
Journal of Gastric Cancer|January 17, 2025
Conversion Therapy for Stage IV Gastric Cancer: Report From the Expert Consensus Meeting at KINGCA WEEK 2024Tae-Han Kim, Ichiro Uyama, Sun Young Rha, et al.
Journal of Immunological Methods|July 23, 2002
A new strategy for the diagnosis of MAGE-expressing cancersJong Wook Park, Taeg Kyu Kwon, In Ho Kim, et al.
Nature Communications|July 10, 2025
DKN-01 and tislelizumab as second-line therapy in DKK1-high gastroesophageal adenocarcinoma: DisTinGuish trial part BKeun-Wook Lee, Devalingam Mahalingam, Byoung Yong Shim, et al.
International Journal of Hematology|March 21, 2014
Multicenter study evaluating the impact of hypomethylating agents as bridging therapy to hematopoietic stem cell transplantation in myelodysplastic syndromesYundeok Kim, In-Ho Kim, Hyeong Joon Kim, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|February 3, 2024
Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trialZev A Wainberg, Yoon-Koo Kang, Keun-Wook Lee, et al.
Journal of Gastric Cancer|May 2, 2023
A Randomized Phase III Study of Patients With Advanced Gastric Adenocarcinoma Without Progression After Six Cycles of XELOX (Capecitabine Plus Oxaliplatin) Followed by Capecitabine Maintenance or Clinical ObservationGuk Jin Lee, Hyunho Kim, Sung Shim Cho, et al.
Pageof 43